Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors

被引：17

作者：

Miles, Dillon H. ^{[1
]}

Yan, Xuelei ^{[1
]}

Thomas-Tran, Rhiannon ^{[1
]}

Fournier, Jeremy ^{[1
]}

Sharif, Ehesan U. ^{[1
]}

Drew, Samuel L. ^{[1
]}

Mata, Guillaume ^{[1
]}

Lawson, Kenneth, V ^{[1
]}

Ginn, Elaine ^{[1
]}

Wong, Kent ^{[1
]}

Soni, Divyank ^{[1
]}

Dhanota, Puja ^{[1
]}

Shaqfeh, Stefan G. ^{[1
]}

Meleza, Cesar ^{[1
]}

Chen, Ada ^{[1
]}

Pham, Amber T. ^{[1
]}

Park, Timothy ^{[1
]}

Swinarski, Debbie ^{[1
]}

Banuelos, Jesus ^{[1
]}

Schindler, Ulrike ^{[1
]}

Walters, Matthew J. ^{[1
]}

Walker, Nigel P. ^{[1
]}

Zhao, Xiaoning ^{[1
]}

Young, Stephen W. ^{[1
]}

Chen, Jie ^{[1
]}

Jin, Lixia ^{[1
]}

Leleti, Manmohan Reddy ^{[1
]}

Powers, Jay P. ^{[1
]}

Jeffrey, Jenna L. ^{[1
]}

机构：

[1] Arcus Biosci Inc, Hayward, CA 94545 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 11期

关键词：

PI3K gamma; inhibitor; selective; azaindole; immunomodulation; cancer;

D O I：

10.1021/acsmedchemlett.0c00387

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The successful application of immunotherapy in the treatment of cancer relies on effective engagement of immune cells in the tumor microenvironment. Phosphoinositide 3-kinase gamma (PI3K gamma) is highly expressed in tumor-associated macrophages, and its expression levels are associated with tumor immunosuppression and growth. Selective inhibition of PI3K gamma offers a promising strategy in immunooncology, which has led to the development of numerous potent PI3K gamma inhibitors with variable selectivity profiles. To facilitate further investigation of the therapeutic potential of PI3K gamma inhibition, we required a potent and PI3K gamma-selective tool compound with sufficient metabolic stability for use in future in vivo studies. Herein, we describe some of our efforts to realize this goal through the systematic study of SARs within a series of 7-azaindole-based PI3K gamma inhibitors. The large volume of data generated from this study helped guide our subsequent lead optimization efforts and will inform further development of PI3K gamma-selective inhibitors for use in immunomodulation.

引用

页码：2244 / 2252

页数：9

共 31 条

[1] Structural comparisons of class I phosphoinositide 3-kinases [J].

Amzel, L. Mario ;

Huang, Chuan-Hsiang ;

Mandelker, Diana ;

Lengauer, Christoph ;

Gabelli, Sandra B. ;

Vogelstein, Bert .

NATURE REVIEWS CANCER, 2008, 8 (09) :665-669

[2]

Bellenie B. R., 2015, Patent No. [WO2015162459A1, 2015162459]

[3]

Cahill Catherine M, 2012, J Signal Transduct, V2012, P358476, DOI 10.1155/2012/358476

[4] Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors [J].

Cassetta, Luca ;

Kitamura, Takanori .

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2018, 6

[5] Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS) [J].

Come, Jon H. ;

Collier, Philip N. ;

Henderson, James A. ;

Pierce, Albert C. ;

Davies, Robert J. ;

Le Tiran, Arnaud ;

O'Dowd, Hardwin ;

Bandarage, Upul K. ;

Cao, Jingrong ;

Deininger, David ;

Grey, Ron ;

Krueger, Elaine B. ;

Lowe, Derek B. ;

Liang, Jianglin ;

Liao, Yusheng ;

Messersmith, David ;

Nanthakumar, Suganthi ;

Sizensky, Emmanuelle ;

Wang, Jian ;

Xu, Jinwang ;

Chin, Elaine Y. ;

Damagnez, Veronique ;

Doran, John D. ;

Dworakowski, Wojciech ;

Griffith, James P. ;

Jacobs, Marc D. ;

Khare-Pandit, Suvarna ;

Mahajan, Sudipta ;

Moody, Cameron S. ;

Aronov, Alex M. .

JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (12) :5245-5256

[6] Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells [J].

De Henau, Olivier ;

Rausch, Matthew ;

Winkler, David ;

Campesato, Luis Felipe ;

Liu, Cailian ;

Hirschhorn-Cymerman, Daniel ;

Budhu, Sadna ;

Ghosh, Arnab ;

Pink, Melissa ;

Tchaicha, Jeremy ;

Douglas, Mark ;

Tibbitts, Thomas ;

Sharma, Sujata ;

Proctor, Jennifer ;

Kosmider, Nicole ;

White, Kerry ;

Stern, Howard ;

Soglia, John ;

Adams, Julian ;

Palombella, Vito J. ;

McGovern, Karen ;

Kutok, Jeffery L. ;

Wolchok, Jedd D. ;

Merghoub, Taha .

NATURE, 2016, 539 (7629) :443-447

[7]

Drew S.L., 2020, J MED CHEM

[8] Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate [J].

Evans, Catherine A. ;

Liu, Tao ;

Lescarbeau, Andre ;

Nair, Somarajan J. ;

Grenier, Louis ;

Pradeilles, Johan A. ;

Glenadel, Quentin ;

Tibbitts, Thomas ;

Rowley, Ann M. ;

DiNitto, Jonathan P. ;

Brophy, Erin E. ;

O'Hearn, Erin L. ;

Ali, Janid A. ;

Winkler, David G. ;

Goldstein, Stanley I. ;

O'Heam, Patrick ;

Martin, Christian M. ;

Hoyt, Jennifer G. ;

Soglia, John R. ;

Cheung, Culver ;

Pink, Melissa M. ;

Proctor, Jennifer L. ;

Palombella, Vito J. ;

Tremblay, Martin R. ;

Castro, Alfredo C. .

ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (09) :862-867

[9] Targeting PI3K-Gamma in Non-Hodgkin Lymphoma [J].

Fruman, David A. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (11) :932-+

[10] PI3K and cancer: lessons, challenges and opportunities [J].

Fruman, David A. ;

Rommel, Christian .

NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (02) :140-156

← 1 2 3 4 →